Linaclotide, a guanylate cyclase C receptor agonist, has shown promising efficacy as a treatment for chronic constipation in a phase IIb, double-blinded, placebo-controlled, dose-ranging trial.
After a quiet few years Merck has returned to the category with soluble guanylate cyclase (sGC) stimulators Adempas (riociguat) and Verquvo (vericiguat) – partnered with Bayer – for PAH and ...
Cyclerion Therapeutics, Inc. has provided an update on its strategic initiatives aimed at facilitating the company's growth. The company is focusing on monetizing its soluble guanylate cyclase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback